参考文献:
[1] 中华医学会风湿病学分会. 2020中国系统性红斑狼疮诊疗指南[J].中华内科杂志, 2020, 59(3): 172-185.
[2] Carter E E, Barr S G, Clarke A E. Nature Reviews Rheumatology, 2016, 12(10):2.605.
[3] 中国系统性红斑狼疮发展报告,第十届中国系统性红斑狼疮研究协作组(CSTAR)/国家风湿病数据中心(CRDC)论坛暨中国风湿免疫病医联体联盟(CRCA)年会
[4] Stohl W & Hilbert DM. Nature Biotechnology.2012; 30(1):69-77.
[5] Mok CC & Lau CS. J Clin Pathol 2003;56:481–490.
[6] 祝文彩,等. 中国误诊学杂志.2007; 7(14):3191-3193.
[7] Cogollo E, et al. Drug Design, Development and Therapy 2015:9 1331–1339.
[8] Samy E, et al. INTERNATIonAL REVIEWS OF IMMUNOLOGY.2017; 36(1):3-19
[9] Wu D, Li J, Xu D, et al. A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study[C]//ARTHRITIS & RHEUMATOLOGY. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2019, 71.